Sood A, Sood C K, Spielvogel B F, Hall I H, Wong O T, Mittakanti M, Morse K
Gross Chemistry Laboratory, Duke University, Durham, N.C. 27706.
Arch Pharm (Weinheim). 1991 Jul;324(7):423-32. doi: 10.1002/ardp.19913240705.
A series of amine carboxyboranes including their amides and esters were synthesized and shown to have potent hypolipidemic activity in rodents at 20 mg/kg/day. Ethylamine carboxyborane, di-n-propylamine-carboxyborane, trimethylamine-carbomethoxyborane, n-butylamine carbomethoxyborane, methylamine-N-ethyl carbamoylborane and trimethylamine-N-n-octyl carbamoylborane were the most potent derivatives demonstrating hypocholesterolemic and hypotriglycemic activities in rats orally at 20 mg/kg/day. These derivatives lowered tissue lipids, e.g. cholesterol, in the rat liver, small intestine and aorta. The fecal lipids were elevated. Furthermore, the agents lowered cholesterol and triglycerides in the serum VLDL and LDL fractions but caused elevations in the HDL fraction after 14 days. The agents inhibited hepatic enzymatic activities of rate limiting steps involved in lipid metabolism, e.g. ATP dependent citrate lyase, sn-glycerol-3-phosphate acyltransferase and phosphatidylate phosphohydrolase.
合成了一系列胺基羧基硼烷及其酰胺和酯,并证明它们在以20毫克/千克/天的剂量给予啮齿动物时具有强大的降血脂活性。乙胺羧基硼烷、二正丙胺羧基硼烷、三甲胺甲氧基羰基硼烷、正丁胺甲氧基羰基硼烷、甲胺-N-乙基氨基甲酰硼烷和三甲胺-N-正辛基氨基甲酰硼烷是最有效的衍生物,在以20毫克/千克/天的剂量口服给予大鼠时表现出降胆固醇和降甘油三酯活性。这些衍生物降低了大鼠肝脏、小肠和主动脉中的组织脂质,如胆固醇。粪便脂质升高。此外,这些药物在14天后降低了血清极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)组分中的胆固醇和甘油三酯,但导致高密度脂蛋白(HDL)组分升高。这些药物抑制了脂质代谢中限速步骤的肝脏酶活性,如ATP依赖性柠檬酸裂解酶、sn-甘油-3-磷酸酰基转移酶和磷脂酸磷酸水解酶。